ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to support the execution of strategic objectives. The new facility expands the Company's three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends the maturity date under each respective loan agreement from October 1, 2025 to April 30, 2027. The additional borrowing capacity provides Solésence with significant financial flexibil
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and
ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/q53hzimg Dial-In Link: https://register-conf.
4 - SOLESENCE, INC. (0000883107) (Issuer)
4 - SOLESENCE, INC. (0000883107) (Issuer)
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and
ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/q53hzimg Dial-In Link: https://register-conf.
8-K - SOLESENCE, INC. (0000883107) (Filer)
10-Q - SOLESENCE, INC. (0000883107) (Filer)
8-K - SOLESENCE, INC. (0000883107) (Filer)